Remdesivir Study Ended Early With No Improvement for COVID-19 Patients

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States, in March 2020. Gilead Sciences via AP

An antiviral drug tested against COVID-19 in patients in China did not quicken their improvement or prevent death, according to results briefly posted online on Thursday.

Remdesivir, developed by Gilead Sciences, is an experimental drug that some experts are optimistic can prove effective against COVID-19, a disease caused by the CCP (Chinese Communist Party) virus, a novel coronavirus.